search
Back to results

The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) (BEZA)

Primary Purpose

X-linked Adrenoleukodystrophy, Adrenomyeloneuropathy

Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Bezafibrate
Sponsored by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for X-linked Adrenoleukodystrophy focused on measuring X-ALD, AMN, adrenomyeloneuropathy phenotype

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • an age of 18 years or older
  • capable of giving informed consent and capable of visiting the hospital for follow-up visits
  • no contra-indications for the use of bezafibrate, e.g. kidney- and/or liver disease.
  • confirmed X-ALD, AMN phenotype (confirmed by VLCFA analysis or analysis of the ABCD1 gene)

Exclusion Criteria:

  • use of medication that lowers cholesterol and/or triglycerides (e.g. statins)
  • liver disease or and increase in serum CK of more than 3 times the baseline level
  • treatment with Lorenzo's oil in the 8 weeks preceding the trial

Sites / Locations

  • Academisch Medisch Centrum

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Bezafibrate

Arm Description

All patients in the trial will use bezafibrate 400 mg once daily until week 12, and subsequently use 800 mg onde daily until week 24.

Outcomes

Primary Outcome Measures

Very long chain fatty acids (VLCFA; C22:0, C24:0 and C26:0) in plasma, lymphocytes and erythrocytes.

Secondary Outcome Measures

Side effects
Cholesterol (total-, HDL, and LDL-cholesterol) in plasma.

Full Information

First Posted
July 13, 2010
Last Updated
August 9, 2011
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
The Stop ALD Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT01165060
Brief Title
The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)
Acronym
BEZA
Official Title
Effect of Bezafibrate on Very Long Chain Fatty Acid Metabolism in Men With X-linked Adrenoleukodystrophy (X-ALD)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2010
Overall Recruitment Status
Completed
Study Start Date
July 2010 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
August 2011 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
The Stop ALD Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
X-linked adrenoleukodystrophy (X-ALD) is an inherited metabolic disorder characterised by accumulation of very long chain fatty acids (VLCFA) in plasma and tissue. Presumably this accumulation is responsible for tissue damage. The disease can cause severe demyelinisation of the central nervous system usually causing death in childhood or progressive ambulatory problems in adults caused by a progressive myelopathy. For the latter category of patients no curative treatment is currently available. Recent investigations in human fibroblasts and mice identified bezafibrate as an agent that might reduce VLCFA in patients with X-ALD. Objective of the study: The trial is designed as an open-label pilot study. The main goal is to investigate if bezafibrate can reduce VLCFA in vivo in patient with X-ALD. If there is indeed a biochemical effect, a large follow-up study will be initiated with clinical outcome parameters. Study design: 10 men with X-ALD will use bezafibrate during a period of 6 months (in combination with a low fat diet). On 6 different time points the participants will undergo a venipuncture for detecting possible side effects and to determine the biochemical outcome parameters. Study population: Adult men with X-linked adrenoleukodystrophy. Intervention (if applicable): Bezafibrate. Primary study parameters/outcome of the study: The primary outcome parameters are cholesterol levels (total-, LDL, and HDL) and levels of triglycerides in plasma, VLCFA levels in plasma, leukocytes and erythrocytes and also C26:0-lyso-PC in bloodspots. Secondary study parameters/outcome of the study (if applicable): Secondary outcome parameters are side-effects (subjective and abnormalities in the safety lab).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
X-linked Adrenoleukodystrophy, Adrenomyeloneuropathy
Keywords
X-ALD, AMN, adrenomyeloneuropathy phenotype

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Bezafibrate
Arm Type
Experimental
Arm Description
All patients in the trial will use bezafibrate 400 mg once daily until week 12, and subsequently use 800 mg onde daily until week 24.
Intervention Type
Drug
Intervention Name(s)
Bezafibrate
Other Intervention Name(s)
Bezalip retard.
Intervention Description
Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
Primary Outcome Measure Information:
Title
Very long chain fatty acids (VLCFA; C22:0, C24:0 and C26:0) in plasma, lymphocytes and erythrocytes.
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Side effects
Time Frame
At 4, 8, 12, 16, 20 and 24 weeks.
Title
Cholesterol (total-, HDL, and LDL-cholesterol) in plasma.
Time Frame
24 weeks

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: an age of 18 years or older capable of giving informed consent and capable of visiting the hospital for follow-up visits no contra-indications for the use of bezafibrate, e.g. kidney- and/or liver disease. confirmed X-ALD, AMN phenotype (confirmed by VLCFA analysis or analysis of the ABCD1 gene) Exclusion Criteria: use of medication that lowers cholesterol and/or triglycerides (e.g. statins) liver disease or and increase in serum CK of more than 3 times the baseline level treatment with Lorenzo's oil in the 8 weeks preceding the trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bwee Tien Poll - The, MD, PhD
Organizational Affiliation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Academisch Medisch Centrum
City
Amsterdam
State/Province
NH
ZIP/Postal Code
1100 DD
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
22911730
Citation
Engelen M, Tran L, Ofman R, Brennecke J, Moser AB, Dijkstra IM, Wanders RJ, Poll-The BT, Kemp S. Bezafibrate for X-linked adrenoleukodystrophy. PLoS One. 2012;7(7):e41013. doi: 10.1371/journal.pone.0041013. Epub 2012 Jul 20.
Results Reference
derived

Learn more about this trial

The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)

We'll reach out to this number within 24 hrs